---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022604"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:32:26.811061+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics Q3 core revenue up 110% to $56M; acquires Fulgent Pharma for ~$100M

## Summary
- Q3 revenue $105.7M (down 54% YoY due to COVID decline); GAAP EPS $0.06, non-GAAP EPS $0.32.
- Core revenue (ex-COVID) grew 110% YoY to $56.0M; adjusted EBITDA $19.7M.
- Acquired Fulgent Pharma for ~$100M (cash + stock), a clinical-stage therapeutics company with nano-drug delivery platform.
- Lead candidate FID-007 for head & neck cancer; combined company offers vertically integrated oncology precision medicine.
- Cash, cash equivalents and investments of $918.0M as of Sep 30, 2022.

## SEC filing metadata
- accession: 0000950170-22-022604
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000095017022022604/0000950170-22-022604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000095017022022604/flgt-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022604
- JSON: https://secwatch.observer/filing/0000950170-22-022604.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022604.txt

## Key facts
- Earnings Releases
  Fulgent Genetics, Inc. reported third quarter ended September 30, 2022 results: revenue $105.7 million, net income $1.7 million, EPS $0.06 per share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $105.7 million
  - Net income: $1.7 million
  - EPS: $0.06 per share
  - Result: reported results
  source text: Exhibit 99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Fulgent Genetics Reports Third Quarter 2022 Financial Results • Revenue totals $105.7 million • Core Revenue grows 110% year-over-year to $56.0 million TEMPLE CITY, CA, November 7, 2022 —Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674930/000095017022022604/0000950170-22-022604-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.